Type I, II, and III interferon signatures correspond to COVID-19 disease severity

Myung-Ho Kim, Shadi Salloum, Jeffrey Y Wang, Lai Ping Wong, James Regan, Kristina Lefteri, Zachary Manickas-Hill, MGH COVID-19 Collection & Processing Team, Jonathan Z Li, Ruslan I Sadreyev, Xu G Yu, Raymond T Chung
doi: https://doi.org/10.1101/2021.03.10.21253317

Article usage

Article usage: March 2021 to November 2024

AbstractFullPdf
Mar 202183521223
Apr 20211582264
May 20211492353
Jun 2021794023
Jul 2021573925
Aug 20211023131
Sep 2021693033
Oct 202161627
Nov 2021723050
Dec 202160322
Jan 2022381217
Feb 2022341417
Mar 202236919
Apr 2022301214
May 202230224
Jun 202227568
Jul 202229661
Aug 202227215
Sep 202235016
Oct 202253214
Nov 20222418
Dec 202223010
Jan 202326215
Feb 20231437
Mar 202320519
Apr 202320113
May 20231235
Jun 202313610
Jul 2023635
Aug 202319146
Sep 20231279
Oct 20231035
Nov 20231424
Dec 2023120112
Jan 2024154145
Feb 20241647
Mar 20245510
Apr 202421911
May 20247210
Jun 202418411
Jul 20249213
Aug 20241237
Sep 20242136
Oct 20242126
Nov 2024102
Back to top
Posted March 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Type I, II, and III interferon signatures correspond to COVID-19 disease severity
Myung-Ho Kim, Shadi Salloum, Jeffrey Y Wang, Lai Ping Wong, James Regan, Kristina Lefteri, Zachary Manickas-Hill, MGH COVID-19 Collection & Processing Team, Jonathan Z Li, Ruslan I Sadreyev, Xu G Yu, Raymond T Chung
medRxiv 2021.03.10.21253317; doi: https://doi.org/10.1101/2021.03.10.21253317
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area